Long-term clinical outcomes with <i>Clostridium butyricum</i> MIYAIRI 588 (CBM588) and TOPOSCORE assessment in patients receiving immune checkpoint inhibitor (ICI)-based combinations for metastatic renal cell carcinoma (mRCC).Sumanta Kumar Pal, Nazli Dizman, Hedyeh Ebrahimi et al.|Journal of Clinical Oncology|2026Cited by 0
Genomic characterization of upper tract urothelial carcinoma (UTUC) with or without sarcomatoid differentiation.Salvador Jaime-Casas, Abhishek Tripathi, Koral Shah et al.|Journal of Clinical Oncology|2026Cited by 0
First results of a dose-escalation study evaluating <i>Clostridium butyricum</i> MIYAIRI 588 (CBM588) with nivolumab/ipilimumab (nivo/ipi) in metastatic renal cell carcinoma (mRCC).Miguel Zugman, Alex Chehrazi-Raffle, Hedyeh Ebrahimi et al.|Journal of Clinical Oncology|2026Cited by 0